The following full text is a publisher’s version.

For additional information about this publication click this link.
http://hdl.handle.net/2066/118630

Please be advised that this information was generated on 2021-07-15 and may be subject to change.
**In Vitro** Drug Response and Efflux Transporters Associated with Drug Resistance in Pediatric High Grade Glioma and Diffuse Intrinsic Pontine Glioma

Susanna J. E. Veringa\(^1,2\), Dennis Biesmans\(^1,2\), Dannis G. van Vuurden\(^1,2\), Marc H. A. Jansen\(^1\), Laurine E. Wedekind\(^2,5\), Ilona Horsman\(^3\), Pieter Wesseling\(^4,6\), William Peter Vandertop\(^5\), David P. Noske\(^2,5\), GertJan J. L. Kaspers\(^1\), Esther Hulleman\(^1,2\)

1 Department of Pediatric Oncology/Hematology, VU University Medical Center, Amsterdam, The Netherlands, 2 Department of Neuro-Oncology Research Group, VU University Medical Center, Amsterdam, The Netherlands, 3 Department of Clinical Genetics, VU University Medical Center, Amsterdam, The Netherlands, 4 Department of Pathology, VU University Medical Center, Amsterdam, The Netherlands, 5 Department of Neurosurgery, VU University Medical Center, Amsterdam, The Netherlands, 6 Department of Pathology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

**Abstract**

Pediatric high-grade gliomas (pHGG), including diffuse intrinsic pontine gliomas (DIPG), are the leading cause of cancer-related death in children. While it is clear that surgery (if possible), and radiotherapy are beneficial for treatment, the role of chemotherapy for these tumors is still unclear. Therefore, we performed an *in vitro* drug screen on primary glioma cells, including three DIPG cultures, to determine drug sensitivity of these tumors, without the possible confounding effect of insufficient drug delivery. This screen revealed a high *in vitro* cytotoxicity for melphalan, doxorubicine, mitoxantrone, and BCNU, and for the novel, targeted agents vandetanib and bortezomib in pHGG and DIPG cells. We subsequently determined the expression of the drug efflux transporters P-gp, BCRP1, and MRPI in glioma cultures and their corresponding tumor tissues. Results indicate the presence of P-gp, MRPI and BCRP1 in the tumor vasculature, and expression of MRPI in the glioma cells themselves. Our results show that pediatric glioma and DIPG tumors *per se* are not resistant to chemotherapy. Treatment failure observed in clinical trials, may rather be contributed to the presence of drug efflux transporters that constitute a first line of drug resistance located at the blood-brain barrier or other resistance mechanism. As such, we suggest that alternative ways of drug delivery may offer new possibilities for the treatment of pediatric high-grade glioma patients, and DIPG in particular.

**Introduction**

Pediatric high grade glioma (pHGG) constitutes 15–20% of pediatric central nervous system tumors [1]. These aggressive tumors are difficult to treat, and are associated with an extremely poor prognosis. The extent of surgical resection is the most important clinical prognostic factor in these patients [2]. Together with radiotherapy, which is a standard component of postoperative management, a 2-year-survival rate of 10–30% for supratentorial HGG has been established [1]. Diffuse intrinsic pontine glioma (DIPG), an infiltrative tumor typically originating in the pons, does not qualify for surgical resection due to its delicate location. In DIPG radiotherapy prolongs progression free survival (PFS) and improves quality of life, yet, the median overall survival (OS) in these children is still only nine months [3]. Unfortunately, no chemotherapeutical regimens or alternative radiation options have successfully improved OS or PFS in children with HGG and DIPG [4,5]. These disappointing results emphasize the need to identify effective drugs. Therefore, we screened a heterogeneous group of primary pHGG cell cultures, including three DIPG cultures, for their sensitivity *in vitro* to different drugs.

To clarify whether a lack of clinical response results from tumor cell resistance or from poor drug delivery to the tumor cells, we also explored the mode of drug resistance in these tumors. In particular, we focused on one of the main mechanisms of drug resistance in the brain mediated by overexpression of ATP-binding cassette (ABC) transporters. Drug delivery to the brain is hampered by the presence of P-glycoprotein (P-gp, ABCB1), breast-cancer-resistance protein (BCRP, ABCG2), and multidrug-resistance-associated proteins (MRPs, ABCG1) [6]. Presence of these transporters on tumor cells or (peri)tumoral vasculature results in active efflux of chemotherapeutics by transmembrane transport, leading to a decrease in intracellular drug levels and subsequently a decrease in their cytotoxic activity [7–9].

Here we show that several classic chemotherapeutic drugs display a high cytotoxicity in primary pediatric glioma cell cultures *in vitro*, in physiologically relevant doses. Immunohistochemical staining on the corresponding tumor tissue indicates the presence of P-gp, MRPI, and BCRP1 on the tumor vasculature, while only...
MRP1 is also expressed in glioma cells. These findings suggest that the presence of all three major drug efflux pumps in the blood-brain-barrier (BBB) may form a first line of resistance of pHGG to treatment with classic chemotherapeutic drugs which by themselves are capable of inducing cytotoxicity in pediatric glioma cells. The drug transporters at the BBB impede drug delivery to the tumor site, while the presence of MRP1 protein in glioma cells themselves, may further protect the tumor cells from chemotherapy.

Results

Tumor and Patient Characteristics

Primary cell cultures were established from tumor material from nine children, aged one week to 11 years, diagnosed with high grade glioma (Table 1). In six patients, the tumor was located supratentorially, among these were five glioblastoma multiforme (GBMs), one anaplastic astrocytoma (AA), and one anaplastic oligodendroglioma. Among the GBMs was one rare case of giant cell GBM. Also, three DIPGs were obtained with different histological grading, including a GBM, an AA WHO grade III, and one diffuse fibrillary astrocytoma. In most cases resections were performed before initiation of therapy, except for one DIPG patient, from whom autopsy material was retrieved approximately two hours after death (VUMC-DIPG-01). Malignancy of the established cell lines was confirmed by determining the chromosomal aberrations, either by array CGH or by classical karyotyping. Apart from VUMC-HGG-06 and VUMC-HGG-07, all cell cultures showed abnormalities, varying from small deletions in VUMC-HGG-02 and -03, to extensive chromosomal changes in VUMC-DIPG-A. Within the VUMC-DIPG-A culture, diverse chromosomal aberrations were identified.

Chemosensitivity of Primary Pediatric High Grade Glioma Cultures

In order to determine the sensitivity of primary pHGG cultures to a series of drugs, a small chemical screen was designed, which included conventional chemotherapeutic drugs of a variety of classes, (anthracyclins, alkylating agents, topoisomerase I/II inhibitors, nitrosoureas, mitotic inhibitors, anti-metabolites), and small molecule inhibitors targeting specific proteins that are often upregulated in pHGG or DIPG (Figure S1, Material and Methods S1). Drug concentrations used were based on IC50 values reported for adult malignant glioma cell lines (Table 2 and 3). The effect of the compounds on cell survival was tested at least four times for each primary culture. Robustness of the assay was assessed by calculating the coefficient of variation (CV = 9.4±3.7) and the Z’ factor for each cell line. Except for VUMC-DIPG-01, all Z’ factors indicated a powerful assay (Z’ = 0.6±0.09). In addition, drug sensitivity of primary human astrocytes was measured, to determine the therapeutic window for the various drugs. As shown in Figure 1a, cell cultures VUMC-HGG-01, and VUMC-DIPG-A were relatively sensitive, with <50% cell survival in response to more than half of the chemotherapeutics. In contrast, VUMC-HGG-05 was the most resistant cell line of the panel, remaining unaffected by the majority of compounds. BrdU incorporation studies showed that this resistance or sensitivity was not correlated to proliferation index (Figure S2, Material and Methods S1). The only drug capable of inducing significant toxicity in VUMC-HGG-05 was melphalan. In general, melphalan, the anthracyclines doxorubicin and mitoxantrone, and BCNU most effectively affected cell survival, followed by etoposide, thiopeta, and carboplatin. Among the novel drugs, bortezomib had a significant anti-glioma effect; in six out of nine cultures, exposure to 100 nM bortezomib resulted in >50% reduction in cell survival. Bosutinib, dasatinib, sorafenib, and olaparib (either as monotherapy or in combination with irradiation), had an effect in approximately 4–5 cell cultures. In VUMC-HGG-05, VUMC-HGG-06, and VUMC-HGG-07 the effect of olaparib increased when combined with irradiation. Although the drug dose ranges in our study overlapped with published IC50 values in cancer cell lines, no or little effect was observed with erlotinib, everolimus, panobinostat, and SB431542 (Figure 1b).

Expression of Drug Efflux Transporters in pHGG

In order to determine whether ABC transporters play a role in the responses of our cell cultures, we assessed the presence of the main ABC transporter proteins P-gp (ABCB1), MRP1 (ABCC1) and BCRP1 (ABCG2). Therefore, Western blotting experiments were performed on the pHGG cell cultures (Figure 2). MRP1 was detected in seven out of nine primary glioma cultures, with a variable intensity (2 low, 5 high expression). High MRP1-expression was detected in VUMC-HGG-01, VUMC-HGG-07, VUMC-DIPG-A, and VUMC-DIPG-B. All cultures were negative for P-gp, and in all except VUMC-HGG-01, BCRP1 was also absent. The MCF7/P-gp and MCF/BCRP1 cell lines were used as a positive control for P-gp, and BCRP1 [10,11], and the 2000/MRP1 cell line for MRP1 [12]. Several bands on the BCRP1 blot appeared at a molecular weight which was higher than expected (229 kD instead of 72 kD) (data not shown). These bands were present in the cell lysates of all glioma cultures, and were of pronounced intensity in the six supratentorial pHGG cultures.

To further explore the role of the various ABC transporters in pHGG, and to assess their presence in the (peritumoral vasculature, immunohistochemistry was performed on tumor tissue sections of the patients corresponding to the cell cultures (Figure 3). A semi-quantitative analysis of the sections was performed to distinguish between tumor cells and endothelial cells of the BBB (Table 4). P-gp was absent in the glioma cell membranes in most tumor sections, but showed a moderate expression in the tumor vasculature in half of the patients. MRP1 was expressed in both the glioma cells, and the tumor vasculature in most sections. Staining of BCRP1 in glioma cells was mostly negative or weak, while the microvasculature showed intense staining in the majority of the sections. Representative pictures are given in Figure 3.

Discussion

Here we show that primary cultures derived from pediatric glioma patients, are sensitive to a number of traditional chemotherapeutics as well as to novel, targeted therapeutics. Moreover, - to our knowledge - we provide the first data on drug sensitivity screening of primary DIPG cultures, suggesting that DIPG per se is not necessarily resistant to chemotherapy.

Although there is a substantial heterogeneity in tumor origin and genetic aberrations, a number of drugs show high cytotoxicity in most cell cultures. Generally, the classical, active chemotherapeutics can be divided into two classes: topoisomerase II inhibitors (mitoxantrone, doxorubicin, and etoposide), and alkylating agents (melphalan, BCNU, carboplatin, and thiopeta). We found that melphalan was the only drug to induce significant cell death in all primary cultures, even in the most resistant glioma culture, which was a giant cell glioblastoma. However, the efficacy of melphalan in pediatric gliomas has not been assessed so it is unknown whether sufficient drug levels can be reached locally in these children. Testing in in vivo glioma models will show whether melphalan has the potential to produce toxicity at levels that can
| VUMC- | Sex | Age | Histology | Location     | Surgery   | Radiotherapy | Chemotherapy                        | Survival | Classical karyotype                  | Deduced copynumber karyotype \(^7\) (array results) |
|-------|-----|-----|-----------|---------------|-----------|--------------|-------------------------------------|----------|-------------------------------------|---------------------------------------------|
| f/m   | years | Gy (cum.) | months |                |           |              |                                     |          |                                     |                                             |
| HGG-01 | f  | 14  | AA  | thalamus | STR  | 54 Gy  | CCNU, vincristine | 15 | –                                    | -X, del(1)(pter12), dup(4)(q12q12), –10, –11, del(12)(pter11.21 del(12)(q15qter), –13, –15, del(16)(p11.2p11.2), –18, del(20)(pter11.2) |
| HGG-02 | f  | 0   | GBM | right frontal lobe | STR | n.a. | n.a. | 0 | 46,XX [10] | dup(10)(q11.2q12) |
| HGG-03 | f  | 1   | GBM | left hemisphere | GTR | – | valproic acid | 6 | 46,XX [20] | del(10)(q11.2q12) |
| HGG-05 | f  | 11  | GC GBM | right frontal lobe | STR | 60 Gy | vincristin, carboplatin, cyclophosphamide, etoposide | 12 | 46,XX(i17)(q10) or add(17)(p?) [2]/40,XX, –6, –13, add(18)(p11.2q22), –19, –20, 21, add(21)(p11.2q11.2) | arr(1–22)Xx2 |
| HGG-06 | f  | 5   | AO  | left hemisphere | STR | 54 Gy | procarbazine, CCNU, vincristine | 84** | 46,XX [13] | arr(1–22)Xx2 |
| HGG-07 | f  | 8   | GBM | thalamus | GTR | – | CCNU, vincristine, prednisone | 24 | 46,XX [10] | arr(1–22)Xx2 |
| DIPG-01 | m  | 5   | GBM | pons | autopsy | 45 Gy* | temozolomide | 9 | 46,XY, del(4)(p12) [3] | – |
| DIPG-A | f  | 4   | AA  | ventral pons | PR | 54 Gy | – | 8 | 44,XX, del(1)(q21qter), dup(7)(pter23), del(7)(q31.32q31.32), del(17)(pter12.2), –18, –21 | 40–44,XX, –4, –5, –6, –7, –8, –10, –11, –12, –13, –14, –15, –16, –17, –18, –19, –20, –21, –22, –23, +1–5mar(cp6/7q–9q10–12q13–14–16q16q17–18q19q22–23q24q25q26) |
| DIPG-B | f  | 3   | DA2 | pons | PR | – | carboplatin, procarbazine, cisplatin, etoposide, vincristine, cyclophosphamide | 18 | 46,XX, del(1)(q12) | dup(1)(q12qter) |

f: female, m: male, AA: anaplastic astrocytoma, GBM: glioblastoma, GC GBM: giant cell glioblastoma multiforme, AO: anaplastic oligodendroglioma, DA2: diffuse fibrillary astrocytoma, GTR: gross total resection, STR: subtotal resection, PR: partial resection. Chemotherapy was administered adjuvant to resection and/or radiotherapy in all treated patients.

*hypofractionated radiotherapy 15 fractions of 3 Gy.

**survivor, n.a.: does not apply.

doi:10.1371/journal.pone.0061512.t001
be attained in situ. BCNU, another alkylating agent, also demonstrated high cytotoxicity in most of our pediatric glioma cultures. However, like melphalan, BCNU is considered ineffective in brain tumors due to its inability to pass the blood-brain barrier. There is some evidence that BCNU-impregnated wafers result in improved survival in adults [13,14] and a case of successful glioblastoma treatment using BCNU wafers in a child has been described [15], suggesting that this might be a potential drug in the treatment of pHGG when delivered locally. For the treatment of DIPG, the use of local delivery, e.g., by convection-enhanced delivery (CED), with BCNU may be an option.

In contrast to the classical chemotherapeutic agents, the targeted drugs did not prove very effective in our experiments, although the tyrosine kinase inhibitors bosutinib (BCR/ABL, Src kinase) and dasatinib (BCR/ABL, Src kinase) and sorafenib (VEGFR, PDGFR, Raf kinase) showed efficacy in some of our glioma cultures. However, we have to keep in mind that the choice of these compounds for our small molecule screen was based on mRNA expression levels reported previously for pHGG and DIPG, but we did not analyze the expression of the targeted proteins in our cells in detail [16]. Thus, these drugs may prove more effective when targeted agents are chosen based on individualized tissue analysis and mutated targets, as also shown in a clinical setting [17]. Besides, it appears that multiple aberrant signaling pathways are involved in gliomas, an effective approach presumably requires combined targeted regimens [18]. Since bortezomib induced cell death in most of our cultures in physiologically relevant doses, therapeutic efficacy may increase by including such proteasome inhibitors in a multi-targeted approach.

[19]. Indeed, a recent phase-1 clinical trial in adults with recurrent malignant glioma reported some clinical activity of bortezomib [20]. Importantly however, pediatric and adult HGGs are two distinct diseases at the molecular level [21–23], which may explain the difference in responses to cytotoxic drugs, of which temozolomide (TMZ) is an illustrative example. TMZ is one of the most commonly used therapeutics for adults with proven efficacy in newly diagnosed and recurrent or progressive gliomas [24], but has not resulted in a better outcome in children with HGG [25], nor DIPG [26]. In fact, also in our primary glioma cultures, temozolomide treatment was ineffective, even when combined with irradiation.

In order to elucidate the differences in effect of drug treatment observed in glioma cultures in vitro, and the clinical responses reported in literature, we investigated the role of drug efflux transporters that belong to the ATP-binding cassette (ABC) superfamily. More precisely, we determined the expression of three major drug efflux transporters present in brain: P-glycoprotein/MDR1 (P-gp), Multidrug Resistant Protein 1 (MRP1), and Breast Cancer Resistance Protein 1 (BCRP1), on both the glioma cells and surrounding tissue. P-gp, encoded by the ABCB1 gene, reduces intracellular drug accumulation by both the glioma cells and surrounding tissue. P-gp is expressed on a large number of endothelial cells of the tumor vasculature in half of the pHGG cultures tested, comparable to the expression in normal brain [29]. No expression of P-gp was detected in glioma cells. These results were confirmed by Western blotting, which showed a complete absence of P-gp protein in primary pHGG cultures. Similar results have been described for adult HGG, where no P-gp was detected in primary adult HGG cultures [30]. Interestingly, however, cell lines derived from human adult glioma generally

### Table 2. Classical drugs used in this study.

| Drug | Mechanism of action | Concentrations used in this study | Published in vitro IC50 in malignant glioma | Published peak plasma concentration in children |
|------|---------------------|----------------------------------|------------------------------------------|-----------------------------------------------|
| BCNU | Alkylating agent    | 100 µM, 1 mM                    | 37 µM [43], 173 µM [44], 467 µM [45]     | not reported                                   |
| Carboplatin | Topoisomerase II | 2 µM, 200 µM                    | 80 uM [46], 8 µM [50]                    | 35–403 µM [53]                               |
| Doxorubicin | Topoisomerase II | 100 nM, 1 uM                    | 500 nM [48], 25.4–103 µM [54]            | 97 µM [57], 258 uM [58]                      |
| Etoposide | Topoisomerase I | 20 uM, 200 µM                   | 8.5 uM [50], 3.3–9.9 µM [55]             | 75 µM (14.6 mg/L) [59]                       |
| Irinotecan | Topoisomerase II | 1 uM, 10 uM                    | not reported, 89 uM [52]                  | 8.3–38.9 µM [56]                              |
| Melphalan | Alkylating agent | 40 uM, 400 µM                   | 35.4–103 µM [53]                         | not reported                                  |
| Mitoxantrone | Topoisomerase II | 100 µM, 1 mM                    | 80 uM [46], 8 µM [50]                    | 35–403 µM [53]                               |
| Paclitaxel | Microtubuli | 10 nM, 100 nM                   | 81 nM [51], 8.3–38.9 µM [56]             | 81 nM [51], 8.3–38.9 µM [56]                  |
| Procarbazine | Alkylating agent | 22 µM, 2.6 mM                   | 80 uM [46], 8 µM [50]                    | 35–403 µM [53]                               |
| Temozolomide | Alkylating agent | 50 uM, 500 µM                   | 71 µM [57], 258 uM [58]                   | 75 uM (14.6 mg/L) [59]                       |
| Thiotepa | Microtubuli | 25 µM, 250 µM                   | 81 nM [51], 8.3–38.9 µM [56]             | not reported                                  |
| Temozolomide | Alkylating agent | 25 µM, 250 µM                   | 81 nM [51], 8.3–38.9 µM [56]             | not reported                                  |
| Vincristine | Microtubuli | 10 nM, 100 nM                   | 81 nM [51], 8.3–38.9 µM [56]             | 81 nM [51], 8.3–38.9 µM [56]                  |
contain P-gp activity, and although ABCB1 gene expression has been reported in adult HGG [31], this was not always confirmed by immunohistochemical staining [32]. Together, these results suggest that the role of P-gp in pediatric glioma patients is limited to the BBB, and that an anti-tumor effect of therapeutics that are substrate for P-gp is not ruled out when these barriers are bypassed by intratumoral administration. Indeed, a significant effect of doxorubicin, the most important substrate for P-gp, is observed in our drug screen.

Breast cancer resistance protein 1 (BCRP1), encoded by the ABCG2 gene, is a relatively recently discovered drug resistance protein that has been detected in a variety of solid tumors [33]. However, the significance of this protein in human gliomas is unclear. At the predicted molecular weight, BCRP1 was only detected in one of our pediatric glioma cultures, although additional bands of higher molecular weight were detected in half of the cultures, suggesting the formation of oligomers [34]. As a half-transporter, BCRP1 dimerizes to form a functional ABC protein, with two ATP-binding domains and two sets of transmembrane regions. Therefore, these high-order oligomers are likely to be non-functional. The absence of BCRP1 on glioma cells that was observed on Western blot, corresponded with the immunohistochemistry results. In all patient samples BCRP1 is intensely expressed in the endothelial cells of the tumor vasculature, as also seen in endothelial cells of normal brain [29], but hardly on the tumor cells themselves.

Multidrug resistant protein 1 (MRP1), encoded by the ABCC1 gene, is suggested to contribute to the chemoresistance of adult human gliomas. In contrast to P-gp, MRP1 decreases intracellular drug accumulation preferentially by unidirectional, ATP-driven export of toxic agents [35]. Our results indicate that there is also a significant role for MRP1 in drug resistance in pediatric high grade glioma. MRP1 protein expression is displayed in most glioma cultures, independently of the histological type and tumor grade. Of note, there are some discrepancies in the detection of MRP1 on Western blot and IHC (most notably in VUMC-HGG-02) that may be explained by tumor heterogeneity. More importantly, however, we could not relate the expression of MRP1 by the cultures to a resistance pattern to substrates of MRP1 in the drug screen. In order to quantify the role of MRP1 in tumor cell resistance mechanisms, a functional inhibitory assay should be performed, preferably using MRP1 knockout mice. In the tumor sections, MRP1 was also visualized in the endothelial cells in all tumors, suggesting that MRP1 could limit the permeability of its substrates, not only in tumor cells but also across tumoral microvessels. Based on these results, it is not likely that substrates for MRP1 will target pediatric glioma in a satisfying manner, even when using local delivery, unless MRP1 function is inhibited.

In conclusion, all three major ABC transporters are active at the BBB, impeding the delivery of chemotherapeutics to the tumor site. There are higher levels of P-gp and BCRP1 in the endothelial cells of the tumor vasculature than in the glioma cells themselves, which is in line with findings in adult glioma [36,37]. Targeting P-gp and BCRP1 in the vasculature might therefore enhance the clinical response to chemotherapeutics by inhibiting barrier function, but has a risk of conveying more toxicity, as both P-gp and BCRP are present in comparable levels in normal brain [29]. Since MRP1 is not only present at the BBB, but also seems to be expressed by glioma cells, this could be an even better clinical target. However, it should be stated that the field of drug resistance is very complex, and functional assays and in vivo studies are required to assess the role of different drug efflux transporters in relation to glioma drug resistance.

Most inhibitors of ABC transporter activity developed thus far have considerable toxic side effects, and therefore have failed to significantly improve chemotherapeutic efficacy in patients [38]. Interestingly, tyrosine kinase inhibitors (TKIs), which are considered among the most promising agents for HGGs, were reported to antagonize ABC-transporter-related drug resistance[39–41]. Therefore, combinations of TKIs, with established chemotherapeutic agents, could hold promise in overcoming drug resistance, although single-agent TKIs did not show much anti-tumor activity in our screen.

Potential limitations of the study are the limited sample size, and the design of the customized drug screen. The drug

### Table 3. Novel drugs used in this study.

| Drugs          | Target                  | Substrate for MRP1 | Substrate for P-gp | Substrate for BCRP | Concentrations used in this study                                                                 | Published in vitro IC_{50} in human cancer cell lines |
|----------------|-------------------------|--------------------|--------------------|-------------------|---------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------|
| Bortezomib     | 26S proteasome          | –                  | +                  | –                 | 10 nM, 100 nM                                                                                                                  | 28.9–48.2 nM (glioma) [63]                           |
| Bosutinib      | c-Abi, Src, HDAC        | +                  | +                  | –                 | 1 uM, 10 uM                                                                                                                    | 1.3 (colorec (64), 5.7 uM (melanoma) [65]            |
| Dasatinib      | BCR/ABL, c-Kit, Src, Ephrin | +                | +                  | +                 | 100 nM, 1 uM                                                                                                                  | 210 nM–1.5 uM (glioma) [66]                          |
| Erlotinib      | EGFR                    | +                  | +                  | +                 | 5 uM, 50 uM                                                                                                                   | 9 uM (glioma) [67]                                   |
| Everolimus     | mTOR                    | –                  | +                  | –                 | 100 nM, 1 uM                                                                                                                  | 271 nM (glioma) [68]                                 |
| Olaparib       | PARP                    | –                  | +                  | +                 | 1 uM, 10 uM                                                                                                                  | 1.42–7.43 uM (glioma) [69]                           |
| Panobinostat   | HDAC                    | –                  | +                  | +                 | 50 nM, 500 nM                                                                                                                 | not reported                                         |
| SB431542       | TGFβ, Alk               | –                  | +                  | +                 | 1 uM, 10 uM                                                                                                                  | 0.1–10 uM (dose range used in in vitro studies) [70]  |
| Sorafenib      | Raf, PDGFR, VEGFR, c-Kit| –                  | +                  | +                 | 2.5 uM, 25 uM                                                                                                                 | 5–20 uM (glioma) [71]                                 |
| Temsirolimus   | mTOR                    | –                  | +                  | –                 | 1 uM, 10 uM                                                                                                                  | 1.4 uM (variety) [72]                                |
| Vandetanib     | EGFR, VEGFR, Ret        | –                  | –                  | +                 | 10 uM, 100 uM                                                                                                                 | 10 uM [73]                                           |

Drug targets, concentrations, and ABC efflux transporter substrate specificity for novel, targeted drugs.
doi:10.1371/journal.pone.0061512.t003
concentrations used in the present study were mainly based on information obtained in adult glioma cell lines, which could bias our results in both directions. The purpose of our screen was to identify potential effective anti-glioma therapeutics, rather than to exclude therapeutics for future protocols. Therefore, it is important to emphasize that therapeutics that were not considered effective in this experimental design, should not necessarily be considered ineffective in pediatric glioma without further exploration, as higher doses might prove successful. When aiming for translation to the clinical situation, in vivo experiments with HGG and DIPG xenograft models will be crucial to further elucidate the role of the drug efflux transporters in relation to drug resistance.

As some of the drugs that display a high toxicity in cultures were never found to be beneficial in clinical trials, the understanding of drug resistance in pHGG is essential for the development of efficient therapies. Our data suggest that the presence of drug efflux pumps in the blood-tumor barrier may constitute an important first line of resistance of pHGG to such treatment, and the efficacy may be further impaired by expression of a subset of these, as well as other drug resistance proteins in the glioma cells themselves. Possible approaches to overcome these mechanisms of resistances are direct intratumoral drug delivery, such as convection enhanced delivery (CED), and the use of drugs that are not substrate for these drug transporters.

Materials and Methods

Processing of Tumor Material and Cell Culture

Single cell cultures were established from biopsy samples derived from pediatric glioblastoma multiforme, anaplastic astrocytoma, anaplastic oligodendroglioma and diffuse intrinsic pontine glioma (DIPG) or from DIPG autopsy samples. Informed consent was obtained according to institutionally-approved protocols. Tumor pieces were collected into DMEM (Dulbecco’s Modified Eagles Medium, PAA Laboratories GmbH, Pasching, Austria) and washed twice with PBS to remove blood clots. Samples were sliced into small (3–5 mm³) pieces and either mechanically dissociated by filtering through a cell strainer (BD Falcon Biosciences, Bedford,
USA), or dissociated by incubation with Accutase (PAA Laboratories GmbH, Pasching, Austria). Single cells were seeded in DMEM-F12, constituted with stable glutamine, 10% fetal bovine serum (PerBio Science Nederland B.V., Etten-Leur, The Netherlands), 1% penicillin/streptomycin (PAA Laboratories GmbH, Pasching, Austria), and 0.5% sodium pyruvate. For primary astrocytes 15% fetal bovine serum was used. Cells were grown at 37°C in a 5% CO2 humified atmosphere.

Karyotyping and Comparative Genomic Hybridization (CGH)

Malignancy of the established cell lines was confirmed by determining the chromosomal aberrations, either by classical karyotyping, or by array CGH. For cytogenetic analysis, cells were harvested according to standard cytogenetic techniques. Briefly, cells were treated with demecolcine (final concentration 0.4 μg/ml; Sigma) for 2 hours, trypsinized, treated with a 75 mM KCl hypotonic solution and finally fixed using methanol:acetic acid (3:1). Metaphase spreads were prepared by dropping the fixed cells on glass slides. Karyotyping was performed on GTG banded metaphase cells. Metaphase spreads were observed using a Zeiss Axioskop 20 microscope. Images were captured using a Cytovision imaging system (Leica-microsystems, United Kingdom). For array CGH, genomic DNA was isolated using the Wizard genomic DNA purification kit (Promega) and hybridized to NimbleGen Human CGH 3x720 K Whole-Genome Tiling v2.0 Arrays (Roche Diagnostics) according to the manufacturer’s instructions. Data analyses were performed using the Nexus 5.0 software.

Drug Screen

The primary pediatric glioma- and astrocyte cultures were exposed to a customized chemical screen, consisting of 21 chemotherapeutic drugs, at dose ranges that were based on published in vitro IC50s in malignant glioma (Table 2 and 3). Fifteen hundred cells were seeded per well in 96-well tissue culture plates. Cells in each well were treated with a different compound at two different concentrations. For treatment with temozolomide and olaparib, treatment was done with paired 96-well plates, where one plate was exposed to 3 Gray in a Gammacell® 220 Research Irradiator (MDS Nordion, Canada) after 24 hours of incubation, and the other plate was a non-irradiated control. After 96 hours cell survival was assessed using the Acumen X3 laser cytometer (TTO Labtech, UK), using 300 mM of 49,6-diamidino-2-phenylindole dihydrochloride (DAPI) (Sigma-Aldrich) as readout. Results were analyzed using Acumen Explorer software, calculating the survival percentage for each compound tested in the assay. Each experiment was performed at least four times. A coefficient of variation (CV) and Z' factor were calculated to assess the reproducibility and robustness of the small molecule screens, where CV = SD/μ and Z' = (1−(3σC+3σE−)/μC−μE)/ [42].

Figure 2. Western blot for detection of P-gp, MRP1, and BCRP1 in pHGG cultures. MW represents approximate molecular weight of these proteins, as indicated at the right. The pHGG lanes were loaded with 20 μg of protein, the lanes with positive controls were loaded with 5 μg of protein. doi:10.1371/journal.pone.0061512.g002
Cell Extraction and Western Blotting

Cell cultures were washed twice in PBS, and cell-free extracts were made by resuspension in lysis buffer (50% Tris/HCl pH7.6, 25% MiliQ, 20% glycerol, 4% Protease Inhibitor Cocktail, 0.5% 1 M Dithiotreitol (DTT), 0.5% NP-40) and sonification. The samples were then centrifuged at 13000 rpm for 10 minutes at 4°C, and the supernatants were subsequently used for Western blotting. Equal amounts of protein were loaded on a 4–12% gradient SDS polyacrylamide gel and transferred to PVDF membranes (Millipore, Amsterdam, The Netherlands). The membranes were washed, blocked with 5% milk, and incubated overnight with an 1:50 diluted antibody against P-gp/ABCB1 (MDR1/clone JSB-1 mab4120, Chemicon, Millipore, Temecula, California), BCRP/ABCG2 (BXP-21 Ab3380, Abcam, Cambridge, United Kingdom), MRP1/ABCC1 (ABCC1 A10 HPA002380, Sigma-Aldrich), or with an 1:15,000 diluted antibody directed against β-Actin (Millipore, MAB1501R). After several washes the membranes were incubated with anti-mouse or anti-rabbit IgG HRP (Dako, Glostrup, Denmark) in a dilution of 1:3,000. Antibody binding was detected using Enhanced Chemiluminescence (GE Healthcare, Buckinghamshire, UK).

Immunohistochemistry

Paraffin-embedded tissue was sliced into 5 μm sections, deparaffinized and rehydrated by washing in xylene and ethanol series. Endogenous peroxidase activity was blocked with 0.3% hydrogen peroxidase in methanol for 30 minutes. The sections were washed and heated in citrate buffer pH6, and gradually cooled to room temperature. After a PBS wash, the sections that were stained for P-gp were blocked with 5% normal goat serum (NGS) in PBS for thirty minutes prior to primary antibody incubation. Sections were incubated for one hour at room temperature with an 1:20 diluted antibody against P-gp (MDR1/clone JSB-1 mab4120, Chemicon, Millipore, Temecula, California), an 1:40 diluted antibody against BCRP1 (BXP-21 Ab3380, Abcam, Cambridge, United Kingdom), or an 1:75 diluted antibody against MRP1 (ABCC1 A10 HPA002380, Sigma-Aldrich). For the detection of the primary antibody, EnVision anti-mouse/anti-rabbit (ImmunoLogic, Duiven, The Netherlands) was used according the manufacturer’s instructions. Peroxidase activity was detected using 3,3-diaminobenzidine-Tetrachloride (DAB) (Sigma, USA) in 0.1% hydrogen peroxide. All sections were counterstained with haematoxylin. Protein expression was scored for quantity (percentage of cells, ranging from 0 = 0, 1 = ≤20%, 2 = 20–40%, 3 = 40–60%, 4 = 60–80%, to 5 = 80–100%), and intensity (0 = absent, 1 = low, 2 = moderate, 3 = high). Using these data, an immunohistochemistry score (IHS) was calculated by multiplying the quantity and staining intensity scores. IHS: 0 = negative, 1–3 = weak, 4–9 = moderate, 10–15 = strong. Images were made using a Zeiss Axioskop microscope (HBO100W/Z), equipped with a Canon digital camera (Canon PowerShot A460, Canon Inc., Tokyo, Japan); imaging software is Canon Utilities, ZoomBrowser Ex. 5.7, Canon Inc, Nort Ryde, Australia.
Table 4. Immunohistochemistry scores of P-gp, Mrp1, and Bcrp1 in tumor tissue sections.

|            | ABCB1/P-gp | ABCB1/Mrp1 | ABCG2/Bcrp1 |
|------------|------------|------------|-------------|
|            | Tumor cells | Vasculature | Tumor cells | Vasculature | Tumor cells | Vasculature |
| VUMC-HGG-01| negative    | weak        | moderate    | moderate    | negative    | strong      |
| VUMC-HGG-02| negative    | moderate    | moderate    | weak        | moderate    | strong      |
| VUMC-HGG-03| negative    | negative    | moderate    | negative    | weak        | weak        |
| VUMC-HGG-05| negative    | weak        | moderate    | weak        | negative    | strong      |
| VUMC-HGG-06| negative    | weak        | weak        | moderate    | weak        | strong      |
| VUMC-HGG-07| negative    | moderate    | moderate    | negative    | weak        | strong      |
| VUMC-DIPG-01| negative    | moderate    | weak        | moderate    | weak        | strong      |
| VUMC-DIPG-A| negative    | moderate    | strong      | negative    | strong      | negative    |
| VUMC-DIPG-B| --          |            |            |            |            |            |

Protein expression was scored for quantity (percentage of cells, ranging from 0 = absent, 1 = low, 2 = moderate, 3 = high), and intensity (0 = absent, 1 = low, 2 = moderate, 3 = high). Using these data, an immunohistochemistry score (IHS) was calculated by multiplying the quantity and staining intensity scores. IHS: 0 = negative, 1–3 = weak, 4–9 = moderate, 10–15 = strong.

doi:10.1371/journal.pone.0061512.t004

Supporting Information

Figure S1 In silico analysis. *In silico* analysis of mRNA expression using R2 analysis software on datasets of non-malignant brain tissue (light blue), versus datasets of pediatric HGG and DIPG (dark blue). (TIF)

Figure S2 Cell proliferation assay, as determined by BrdU incorporation. Immunofluorescence showing the percentages of BrdU incorporation (green) as compared to DAPI staining (blue) in VUMC-HGG-01, VUMC-HGG-05, and VUMC-DIPG-A. (TIF)

References

1. Broniscer A, Gajjar A (2004) Supratentorial high-grade astrocytoma and diffuse brainstem glioma: two challenges for the pediatric oncologist. Oncologist 9: 197–206.
2. Tamber MS, Rutka JT (2005) Pediatric supratentorial high-grade gliomas. Neurosurg Focus 14: e1.
3. Jansen MHA, van Vuuren DG, Vandertop WP, Kaspers GJL (2012) Diffuse intrinsic pontine gliomas: a systematic update on clinical trials and biology. Cancer Treat Rev 38: 27–35.
4. Hargrave D, Bartels U, Boull et E (2006) Diffuse brainstem glioma in children: critical review of clinical trials. Lancet Oncol 7: 241–248.
5. Broniscer A (2006) Past, present, and future strategies in the treatment of high-grade glioma in children. Cancer Invest 24: 77–81.
6. Ueno M, Nakagawa T, Wu B, Onodera M, Huang CL, et al. (2010) Transporters in the brain endothelial barrier. Curr Med Chem 17: 1125–1130.
7. Bredel M (2001) Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35: 161–204.
8. Nis AT (2007) The role of membrane transporters in drug delivery to brain tumors. Cancer Lett 254: 11–29.
9. Dedes X, Amiel A, Delattre JV, Scherrmann JM (2006) Role of ABC transporters in the chemoresistance of human gliomas. Curr Cancer Drug Targets 6: 433–445.
10. Doyle LA, Yang W, Abruzzo LV, Kroghmann T, Gao Y, et al. (1998) A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci U S A 95: 15665–15670.
11. Whelan RD, Waring CJ, Wolf CR, Hayes JD, Hossing LF, et al. (1992) Overexpression of Pglycoprotein and glutathione S-transferase pi in MCF-7 cells selected for vincristine resistance in vitro. Int J Cancer 52: 241–246.
12. Hooijberg JH, Peters GJ, Assaraf YG, Kathmann I, Priest DG, et al. (2003) The role of multidrug resistance proteins Mrp1, Mrp2 and Mrp3 in cellular folate homeostasis. Biochem Pharmacol 63: 765–771.
13. Dixit S, Hingorani M, Achawal S, Scott I (2011) The sequential use of vincristine and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review. Br J Neurosurg 25: 459–469.
14. Hart MG, Grant R, Garside R, Rogers G,Somerville M, et al. (2011) Chemosensitization for high grade glioma. Cochrane Database Syst Rev CD007294.
15. Marquez-Rivas J, Ramirez G, Oller-Muñoz A, Gimeínez-Pando J, Emmerich J, et al. (2010) Initial experience involving treatment and retreatment with carmustine wafers in combination with oral temozolomide: long-term survival in a child with relapsed glioblastoma multiforme. J Pediatr Hematol Oncol 32: e202–e206.
16. Paugh BS, Qu C, Jones C, Liu Z, Damovice-Brice M, et al. (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28: 3061–3068.
17. Wolff J, Brown R, Buryanek J, Pilsner S, Vats T, et al. (2011) Preliminary experience with personalized and targeted therapy for pediatric brain tumors. Pediatr Blood Cancer.
18. Stormel JM, Kimmelman AC, Ying H, Nabioullin R, Pusnogi AH, et al. (2007) Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science 318: 297–299.
19. Horton TM, Patti D, Plon SE, Thompson PA, Bongarsa LR, et al. (2007) A phase 1 study of the proteasome inhibitor bortezomib in pediatric patients with refractory leukemias. Children’s Oncology Group study. Clin Cancer Res 13: 1516–1522.
20. Phuphanich S, Supko JG, Carson KA, Grossman SA, Burt Nabors L, et al. (2010) Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma. J Neurosurg 100: 93–101.
21. Suri V, Das P, Pathak P, Jain A, Sharma MC, et al. (2009) Pediatric glioblastomas: a histopathological and molecular genetic study. Neuro Oncol 11: 274–280.
22. Qu H, Jacob K, Faist S, Ge B, Barnett D, et al. (2010) Genome-wide profiling using single-nucleotide polymorphism arrays identifies novel chromosomal imbalances in pediatric glioblastomas. Neuro Oncol 12: 153–163.
23. Paugh BS, Qu C, Jones C, Liu Z, Damovice-Brice M, et al. (2010) Integrated molecular genetic profiling of pediatric high-grade gliomas reveals key differences with the adult disease. J Clin Oncol 28: 3061–3068.

Material and Methods S1 Supplementary Material and Methods.

(DOCX)

Acknowledgments

We thank Tom Würdinger for useful comments and discussion and Pino Poddighe for technical assistance.

Author Contributions

Conceived and designed the experiments: EH DV GK DN WPV PW. Performed the experiments: SH LW DB MJ. Analyzed the data: SV EH DV MJ. Contributed reagents/materials/analysis tools: MJ DV PN. Wrote the paper: SV EH DV WPV PW GK.
24. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJR, et al. (2009) Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10: 459–466.

25. Cohen KJ, Polo SF, Reardon DA, Butler MS, Friedman HS, et al. (2013) Temozolomide in the treatment of high-grade gliomas in children: a report from the Children’s Oncology Group. Neuro Oncol 15: 317–323.

26. Cohen KJ, Heideman RL, Zhou T, Holmes EJ, Lavey RS, et al. (2011) Temozolomide in the treatment of children with newly diagnosed diffuse intrinsic pontine gliomas: a report from the Children’s Oncology Group. Neuro Oncol 13: 410–416.

27. Bredel M, Zumer J (2002) Brain-tumor drug resistance: the basic essentials. Lancet Oncol 3: 497–496.

28. Cordon-Cardo C, O’Brien JP, Casals D, Rittman-Grauer L, Biedler JL, et al. (1989) Multidrug-resistance gene (Pglycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc Natl Acad Sci U S A 86: 685–688.

29. Henson JW, Cordon-Cardo C, Posner JB (1992) P-glycoprotein expression in brain tumors. J Neurol Oncol 14: 261–267.

30. Ni Z, Bikadi Z, Rosenberg MF, Mao Q (2010) Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab 11: 603–617.

31. Itami T, Jensen U, Hansen A, Covitz KM, Zhan Z, et al. (2002) Use of peptide antibodies to probe for the minoantoxine-resistance-associated protein MRP1/BCRP/ABCG2. Biochim Biophys Acta 1565: 6–16.

32. Bredel M (2001) Anticancer drug resistance in primary human brain tumors. Brain Res Brain Res Rev 35: 161–204.

33. Henson JW, Cordon-Cardo C, Posner JB (1992) Pglycoprotein expression in brain tumors. J Neurol Oncol 14: 37–43.

34. Savada T, Kato Y, Sakayori N, Takekawa Y, Kobayashi M (1999) Expression of the multidrug-resistance P-glycoprotein (Pgp, MDR-1) by endothelial cells of the neovascularature in central nervous system tumors. Brain Tumor Pathol 16: 23–27.

35. Shukla S, Wu CP, Ambudkar SV (2000) Development of inhibitors of ATP-binding cassette drug transporters: present status and challenges. Expert Opin Drug Metab Toxicol 4: 205–223.

36. Azzariti A, Porcelli L, Simone GM, Quatrale AE, Colabufo NA, et al. (2010) Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. Cancer Chemother Pharmacol 65: 333–346.

37. Shi Z, Peng XX, Kim W, Shukla S, Si QS, et al. (2007) Erlotinib (Tarceva, OSI-274) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2 mediated drug resistance. Cancer Res 67: 11019–11026.

38. Mi Yj, Liang Yj, Huang HB, Zhao HY, Wu CP, et al. (2010) Apatinib (AMG 386), a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2, selectively inhibits the proliferation and invasion of human glioblastoma cell lines. Mol Cancer 9: 13.

39. Fruehauf JP, Brem H, Brem S, Sloan A, Barger G, et al. (2006) In vitro drug response of glioblastoma tumor spheroids to the anti-cancer drug temozolomide. Anticancer Drugs 17: 109–117.

40. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H (1999) Chemosensitivity of glioma cells in vitro: a meta-analysis. J Cancer Res Clin Oncol 125: 481–486.

41. Moore AS, Norris R, Price G, Nguyen T, Ni M, et al. (2011) Vincristine, melphalan, and corticosteroids significantly reduce the proliferation and autophagic cell death of malignant human glioma cells. J Neurooncol 101: 279–287.

42. ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2, antagonizes the proliferation of malignant glioma cells. Mol Cancer Ther 3: 737–745.

43. Homsi J, Cubitt CL, Zhang S, Munster PN, Yu H, et al. (2009) Src activation in malignant glioma cells. J Neurooncol 92: 410–416.

44. Styczynski J, Olszewska-Slonina D, Kolodziej B, Napieraj M, Wysocki M (2006) Effect of aminosteroids on the proliferation of human glioblastoma cell lines. Int J Pharm 323: 107–110.

45. Premkumar DR, Jane EP, Sathornsumetee S, Reese ED, Herbstreith J, et al. (2011) High dose thiotepa in children undergoing autologous bone marrow transplantation. Bone Marrow Transplant 10: 171–173.

46. Wolff JE, Trilling T, Molenkamp G, Egeler RM, Jurgens H (1999) Chemosensitivity of glioma cells in vitro: a meta-analysis. J Cancer Res Clin Oncol 125: 481–486.